Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program

Pathology - Tập 48 - Trang 535-542 - 2016
Adrienne L. Morey1, Belinda Brown1, Gelareh Farshid2,3,4, Stephen B. Fox5, Glenn D. Francis6,7, Glenda McCue8, Vita von Neumann-Cosel9, Michael Bilous10,11
1SydPath, St Vincent’s Hospital, Sydney, NSW, Australia
2Divisions of Surgical Pathology and Cytopathology, SA Pathology, Adelaide, Australia
3BreastScreen SA, Australia
4Discipline of Medicine, Adelaide University, SA, Australia
5The Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne, Vic, Australia
6Griffith University, Gold Coast, Australia
7University of Queensland, St Lucia, QLD, Australia
8Woolomin Consulting, Wheeo, NSW, Australia
9Roche Products Pty Ltd, Dee Why, NSW, Australia
10Healthscope Pathology, Norwest Private Hospital, Bella Vista, NSW, Australia
11Western Sydney University, Sydney, NSW, Australia

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Pathology

Tập 48

535-542

Thông tin tác giả